Based on the provided incomplete data, a realistic financial newswire statement would be: HIKMA announced today that it received FDA approval for its Abbreviated New Drug Application # ANDA065410, a generic breakthrough therapy that company executives expect to significantly expand the company's market share in the segment once commercialized in 2009.